O-(cyclohexyl(phenyl)methyl)hydroxylamine | 1160488-38-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-(cyclohexyl(phenyl)methyl)hydroxylamine
• 英文别名: O-[cyclohexyl(phenyl)methyl]hydroxylamine
• CAS: 1160488-38-9
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: ZPMGLJJOJGXHQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  O-(cyclohexyl(phenyl)methyl)hydroxylamine 在 盐酸 作用下， 以 乙醚 、 水 为溶剂， 以87%的产率得到O-(cyclohexyl(phenyl)methyl)hydroxylamine hydrochloride
  参考文献：
  名称：

  Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase

  摘要：

  Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer. Significant evidence implicates them in a range of inflammatory and immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control. Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research. This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.11.010
• 作为产物：
  描述：

  环己基(苯基)甲醇 在 N-羟基邻苯二甲酰亚胺 、 偶氮二甲酸二异丙酯 、 三苯基膦 、 一水合肼 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 O-(cyclohexyl(phenyl)methyl)hydroxylamine
  参考文献：
  名称：

  Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase

  摘要：

  Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer. Significant evidence implicates them in a range of inflammatory and immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control. Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research. This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.11.010

文献信息

• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15
• [EN] IDO INHIBITORS<br/>[FR] INHIBITEURS DE L'IDO
  申请人：NEWLINK GENETICS

  公开号：WO2009073620A2

  公开（公告）日：2009-06-11

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.
• [EN] 1,2,4-TRIAZINE DERIVATIVE<br/>[FR] DÉRIVÉ DE 1,2,4-TRIAZINE<br/>[JA] １，２，４－トリアジン誘導体
  申请人：SHIONOGI & CO

  公开号：WO2017204318A1

  公开（公告）日：2017-11-30

  本発明は、新規なＰ２Ｘ3および／またはＰ２Ｘ2/3受容体拮抗作用を有する化合物を提供する。　式（Ｉ）：（式中、Ｒ１は置換若しくは非置換のアルキル等、Ｒ２は置換若しくは非置換の芳香族炭素環式基等、Ｒ３はハロゲン等、Ｒ４ａはそれぞれ独立して水素原子等、Ｒ４ｂはそれぞれ独立して水素原子等、ｎは０～４の整数、Ｘは－Ｎ（Ｒ５）－等、Ｒ５は水素原子等、ｓは０～３の整数）で示される化合物またはその製薬上許容される塩。
• [EN] 5-OXO-1,2,4-TRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF<br/>[FR] DÉRIVÉ DE 5-OXO-1,2,4-TRIAZINE ET COMPOSITION PHARMACEUTIQUE CORRESPONDANTE<br/>[JA] ５－オキソ－１，２，４－トリアジン誘導体およびその医薬組成物
  申请人：SHIONOGI & CO

  公开号：WO2017204316A1

  公开（公告）日：2017-11-30

  本発明は、新規なＰ２Ｘ3および／またはＰ２Ｘ2/3受容体拮抗作用を有する化合物を提供する。　式（Ｉ）：（式中、Ｒ１は置換若しくは非置換のアルキル等、Ｒ２は置換若しくは非置換の芳香族炭素環式基等、Ｒ３は置換若しくは非置換の芳香族炭素環式基等、Ｒ４ａはそれぞれ独立して水素原子等、Ｒ４ｂはそれぞれ独立して水素原子等、ｎは０～４の整数、Ｘは－Ｎ（Ｒ５）－等、Ｒ５は水素原子等）で示される化合物またはその製薬上許容される塩。